Shots:

• NIH has launched LUCA Biologics in Cambridge- Massachusetts focusing on women’s health by initially targeting UTI with its anticipated clinical study and initiation of recruitment of patients in H2’19
• LUCA initiates with a strain bank and gene catalog developed over 15yrs. from Gates Foundation and NIH-funded research and has built a metagenomic and metatranscriptomic platform to identify & validate strains modulating vaginal and urogenital microbiome
• LUCA Biologic is a biotechnological company developing therapies focusing on women’s health with a pipeline targeting UTI- bacterial vaginosis (BV)- and preterm birth (PTB)

Click here to­ read full press release/ article | Ref: PRNewswire | Image: GBI Monthly